Inventiva S.A. (EPA:IVA)
France
· Delayed Price · Currency is EUR | Market Cap | 263.55M |
| Revenue (ttm) | 14.72M |
| Net Income (ttm) | -184.21M |
| Shares Out | 95.66M |
| EPS (ttm) | -3.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,058 |
| Average Volume | 24,051 |
| Open | 2.750 |
| Previous Close | 2.750 |
| Day's Range | 2.745 - 2.760 |
| 52-Week Range | 1.434 - 3.670 |
| Beta | 0.72 |
| RSI | 56.38 |
| Earnings Date | Mar 26, 2025 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, Fra... [Read more]
Financial Performance
In 2024, Inventiva's revenue was 14.72 million, a decrease of -36.43% compared to the previous year's 23.16 million. Losses were -184.21 million, 66.8% more than in 2023.
Financial StatementsNews
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused o...
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutica...
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Daix (France), New York City (New York, United States), January 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...
Inventiva secures €21.4 million
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...
Inventiva reports 2024 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the devel...
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA (NASDAQ: IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro . The company announ...
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA IVA stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro.
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply in today's pre-market trading . Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2....
Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study
Inventiva secures €94.1 million financing for Phase 3 trial of lanifibranor with potential €348 million funding, led by top investors.
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...